USSTOCK.TODAY
Market Closed
Log in Sign up

Curanex Pharmaceuticals Inc(CURX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today

CURX
CURX
Curanex Pharmaceuticals Inc
At close Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$4.44
-0.26 ▼ -5.53%
Nov 19 at 4:00 PM ET (Korea 11/20 06:00)
$4.44
+0.00 +0.00%

Full metrics table

Index ⓘ -P/E ⓘ -EPS (ttm) ⓘ -8.57Insider Own ⓘ 61.35%Shs Outstand ⓘ 1.6MPerf Week ⓘ -21.69%
Market Cap ⓘ 0.01BForward P/E ⓘ -EPS next Y ⓘ -Insider Trans ⓘ -Shs Float ⓘ 0.6MPerf Month ⓘ -11.38%
Enterprise Value ⓘ 0.01BPEG ⓘ -EPS next Q ⓘ -Inst Own ⓘ 0.83%Short Float ⓘ 0.97%Perf Quarter ⓘ -5.73%
Income ⓘ -0.01BP/S ⓘ -EPS this Y ⓘ -Inst Trans ⓘ 4.89%Short Ratio ⓘ 0.28Perf Half Y ⓘ -32.32%
Sales ⓘ 0.00BP/B ⓘ 2.74EPS next 5Y ⓘ -ROA ⓘ -140.31%Short Interest ⓘ 0.01MPerf YTD ⓘ -32.85%
Book/sh ⓘ 1.62P/C ⓘ 4.41EPS past 3/5Y ⓘ -1369.89% -ROE ⓘ -146.46%52W High ⓘ -66.7% ($13.33)Perf Year ⓘ -49.69%
Cash/sh ⓘ 1.01P/FCF ⓘ -Sales past 3/5Y ⓘ -ROIC ⓘ -417.44%52W Low ⓘ 24.16% ($3.58)Perf 3Y ⓘ -
Dividend Est. ⓘ -EV/EBITDA ⓘ -EPS Y/Y TTM ⓘ -836.88%Gross Margin ⓘ -Volatility(W/M) ⓘ 6.16% 7.14%Perf 5Y ⓘ -
Dividend TTM ⓘ -EV/Sales ⓘ -Sales Y/Y TTM ⓘ -Oper. Margin ⓘ -ATR (14) ⓘ 0.46Perf 10Y ⓘ -
Dividend Ex-Date ⓘ -Quick Ratio ⓘ 17.84EPS Q/Q ⓘ -175.83%Profit Margin ⓘ -RSI (14) ⓘ 38.26Recom ⓘ -
Dividend Gr. 3/5Y ⓘ -Current Ratio ⓘ 17.84Sales Q/Q ⓘ -SMA20 ⓘ -16.05% ($5.29)Beta ⓘ -2.72Target Price ⓘ -
Payout ⓘ -Debt/Eq ⓘ 0.21Earnings ⓘ -SMA50 ⓘ -10.46% ($4.96)Rel Volume ⓘ 0.14Prev Close ⓘ $4.7
Employees ⓘ 6LT Debt/Eq ⓘ 0.16EPS/Sales Surpr. ⓘ -SMA200 ⓘ -26.93% ($6.08)Avg Volume(3M) ⓘ 0.02MPrice ⓘ $4.44
IPO ⓘ 2025/8/26Option/Short ⓘ No/YesTrades ⓘ 437Volume ⓘ 2,986Change ⓘ -5.53%
Company
CURX CURXCuranex Pharmaceuticals Inc | NASD | Biotechnology Deep dive

🌿 Quronex Pharmaceuticals is a pre-clinical-stage biotech company developing single-component, plant-derived anti-inflammatory drug candidates. Its lead candidate, Phyto-N, has demonstrated efficacy in animal models of multiple inflammatory diseases, including ulcerative colitis, atopic dermatitis, diabetes, non-alcoholic fatty liver disease, and gout. The company became listed via a Nasdaq IPO in August 2025 and is preparing to initiate a Phase 1 clinical trial in Australia, positioning it as a newly listed micro-cap biotech.

Quote

Over the past 1 year, on the lower side

67% below its 1-year high.

Now $4.44
52w low$3.5852w high$13.33
52W Range9%
Volume ⓘ 2,986

Traded less than usual. That is 14% of its average volume.

D
Overall · many cautions
We judged 3 of the 8 questions below. 2 need caution.
No data for growth, valuation, earnings, outlook, dividends, or not applicable.
Peer comparison Biotechnology

It ranks #519 of 598 in the industry

Based on market cap of $7M.

FAQ

FAQ

What kind of company is CURX?

CURX belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of CURX?

The market cap of CURX is approximately $7M, ranking 5,469 within its sector.

What is the 52-week high and low for CURX?

CURX has recorded a 52-week high of $13.33 and a low of $3.58.

Telegram KakaoTalk
Briefs · earnings · signals, first Telegram · KakaoTalk channels